Myeloma, multiple
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
The commonly assumed target, RB1, showed complete LOF in 3.2% of patients, while DIS3 complete LOF was detected in 6.9% of patients; however, a striking number of additional genes were independently knocked out in myeloma (Fig. 1b). The following two contiguous gene regions with complete ...
Multiple myeloma (MM) is the second most common hematologic malignancy after non-Hodgkin’s lymphoma. Intrinsic and acquired drug resistance of cancer cells to standard drugs is a major obstacle for a more successful survival outcome of MM patients treated on contemporary clinical protocols. The prim...
Gene expression profiling (GEP) has significantly contributed to the elucidation of the molecular heterogeneity of multiple myeloma plasma cells (MMPC) and only recently it has been recommended for risk stratification. Prior to GEP MMPC need to be enriched resulting in an inability to immediately fr...
In myeloma cells, the transcription factor IRF4, the master regulator of plasma cells, is aberrant... S Ikeda,H Tagawa - 《Cancer Science》 被引量: 0发表: 2021年 Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease et al.:...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
Vitro experiments have shown that PAC-1 exhibits cytotoxicity against lymphoma, multiple myeloma, and many other cancer cells [42]. Currently, PAC-1 has been used in clinical trials for the treatment of various tumors, including but not limited to lymphoma, melanoma, solid tumors, breast cancer...
Multiple myeloma (MM) is an incurable plasma cell malignancy, which is predominantly a disease of older adults (the median age at diagnosis is 70 years). The slow progression from asymptomatic stages and the late-onset of MM suggest fundamental differences compared to many other hematopoietic syste...
1.A method for assessing sensitivity of multiple myeloma cells obtained from a subject to chemotherapeutic agents in an ex vivo assay comprising:contacting the multiple myeloma cells obtained from the subject with at least one chemotherapeutic agent ex vivo;incubating the multiple myeloma cells with th...